Resource use and risk factors in high-cost exacerbations of COPD.
about
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary diseaseComputer and mobile technology interventions for self management in chronic obstructive pulmonary diseaseSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseasePulmonary rehabilitation following exacerbations of chronic obstructive pulmonary diseasePulmonary rehabilitation following exacerbations of chronic obstructive pulmonary diseaseSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseRespiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic reviewPulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.Risk factors of hospitalization and readmission of patients with COPD exacerbation--systematic review.The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settingsImproving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, CanadaThe prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008.Association between lung function and exacerbation frequency in patients with COPD.Markers of exacerbation severity in chronic obstructive pulmonary diseaseEconomic Impact of Leading Prosperity Diseases: COPD in South East Europe.Utility estimation of hypothetical chronic obstructive pulmonary disease health states by the general population and health professionalsAssessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease.The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units.Patient characteristics associated with risk of first hospital admission and readmission for acute exacerbation of chronic obstructive pulmonary disease (COPD) following primary care COPD diagnosis: a cohort study using linked electronic patient recIdentifying Distinct Healthcare Pathways During Episodes of Chronic Obstructive Pulmonary Disease Exacerbations.Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease.Role of N-acetylcysteine in the management of COPDStrategies for improving outcomes of COPD exacerbationsChronic airflow limitation in developing countries: burden and priorities.Role of macrolide therapy in chronic obstructive pulmonary disease.Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom.The impact of body mass index on inpatient- versus outpatient-treated chronic obstructive pulmonary disease exacerbationsExplaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis.Triple therapy for the management of COPD: a review.Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice?Management of COPD exacerbations in primary care: a clinical cohort study.Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.Predicting Healthcare Utilization by Patients Admitted for COPD Exacerbation.Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates.Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients.
P2860
Q24187361-AB006A0C-5682-456E-97D7-6FA5CC83C9BDQ24187636-0ACB7B84-4705-4AC6-9D8C-6F69B32661E1Q24193908-5782AE85-80DC-4D41-ACC3-E4ED21B237F6Q24200476-355D8E6C-449C-4EF1-919D-2C32829185CBQ24236241-632AFF65-5909-4627-B1B1-04C95EE04668Q24241029-DEB97458-87DA-4BDF-95E5-DEB2B3B536AEQ24241135-5ACB002E-A492-41BC-BEF1-9CB30EFA20FCQ24814417-4625EB5E-BC94-40A3-8473-A781123B1930Q30240148-02B83716-8511-40EF-B8F8-C38A8191ECBAQ33317002-F1A0B478-681A-45CC-B71E-5C7D81444AF0Q33532293-7612A07B-D1A4-4B5A-AC6B-DBCCBB9859ACQ33794408-B21B2F2A-FE0D-43C9-BF92-D1C9E1678F1CQ33868106-C1781A4E-5B49-49A0-AFBB-A9A5C4219160Q34303093-43D8F525-BF30-47D3-A4CA-784C95092BA1Q34432556-8EBF3396-8823-4705-8732-8CDEA2F8CCA6Q34691221-5878EB06-8F14-42F7-A39A-721FA626FBBDQ35211495-5E031466-5B7E-4D4F-9F0E-E83BDBD8843DQ35238199-29E8F8C5-E753-4017-9887-1898DD766D06Q35537594-97FFFD04-4511-450B-931D-8CEF7E245B27Q35876360-537A7DCB-C67C-4FE8-960A-03BBEF373C6CQ36240664-DD6F8BD9-5332-4617-A86F-D06BEC80CFC1Q36526797-6D549491-ACBC-4322-AA0F-1485FBE21A68Q36663922-BD38D5F5-6C02-43E2-BFAF-F7911EC3B08CQ36765787-07828810-6A7E-473A-9960-4562609EC193Q37017349-C1355EDD-A2B1-48D2-8543-5D2B55E9CF62Q37018847-F3F973CD-63AB-448A-AD7A-DE9B7D80053DQ37225477-6649F98A-13FC-4784-B85A-A1B005E8428BQ37319950-083DCE4D-F1F9-4E9C-9B07-BB9CF0C89759Q37470650-03AA93A9-CBFC-4C0A-8FE9-4AEAD205DD3EQ37641193-8F9FC233-7846-4008-8A33-306248D44433Q37701943-8B8E63BD-76D8-4655-82E7-A9990BBD4E0EQ37868010-ED79A878-B402-4560-B0B4-1E163768C663Q37992679-D0750E3D-53B2-42BE-81CD-B2EC892BE946Q38109057-6F0D7BDF-FF16-45B2-BD88-2E120EF7D27DQ38151518-A3BFF234-A6CF-4D61-B90C-2D6F0FC3C039Q38768853-3D6CCB63-7418-4568-B3AE-8D89E784524BQ38939466-53E560E2-D635-44BF-9B52-995C5A1C19ACQ39246070-8BD462D6-98A2-4195-8A18-25C2F4451AEDQ40267745-A5E59DA2-84BB-4805-92C0-39B70C71252BQ40833745-E7A6A10C-932F-4C89-8A24-A496206ED111
P2860
Resource use and risk factors in high-cost exacerbations of COPD.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Resource use and risk factors in high-cost exacerbations of COPD.
@en
Resource use and risk factors in high-cost exacerbations of COPD.
@nl
type
label
Resource use and risk factors in high-cost exacerbations of COPD.
@en
Resource use and risk factors in high-cost exacerbations of COPD.
@nl
prefLabel
Resource use and risk factors in high-cost exacerbations of COPD.
@en
Resource use and risk factors in high-cost exacerbations of COPD.
@nl
P1433
P1476
Resource use and risk factors in high-cost exacerbations of COPD.
@en
P2093
Jan B Oostenbrink
Maureen P M H Rutten-van Mölken
P304
P356
10.1016/J.RMED.2004.02.013
P577
2004-09-01T00:00:00Z